

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ANNOUNCEMENT REGARDING CLARIFICATION OF MEDIA REPORTS

This announcement is made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) to clarify media reports on 13 January 2016.

I. MEDIA REPORTS

Recently, some media and websites published an article titled *Good Results of Baiyunshan Promoting Share Price*, in which it referred to the relevant information of future profit forecast of the Company. It reported that: “The Company is expected to achieve sales revenue of RMB20.1 billion, RMB21.2 billion and RMB22.9 billion for the years from 2015 to 2017, with a year-on-year growth of 7.07%, 5.56% and 8.02%, and will realize a net profit of RMB1.38 billion, RMB1.52 billion and RMB1.75 billion, with a year-on-year growth of 13.01%, 10.48% and 14.79%.”

II. CLARIFICATION

We hereby make following clarification as regard to the contents of the media reports after investigation:

1. The contents of the media reports are mainly extracted from research reports of analysts of securities companies and the related media did not have any interview with the Company in relation to the media reports; and the Company had never released any information to the media in relation to the Company’s future profit forecast as contained in the media reports;
2. For the inaccurate reports made by the media, the Company reserves the right to take legal actions against relevant parties.

III. NECESSARY NOTICE

The Company hereby draws attention of its shareholders and investors that the designated media for publication of its information includes Shanghai Securities News, Securities Times, China Securities Journal, Securities Daily and the websites of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Shareholders and investors are advised to pay attention to the investment risks.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 13 January 2016

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.